Table 5.
Selected immunotherapy trials in malignant mesothelioma
| Trial name | Phase | Therapy | mOS | 1-year OS | DOR | mPFS (weeks) | 1-year PFS | mORR (%) | Ref |
| DETERMINE | 2b | Tremelimumab | 7.7 | NR | NR | NR | NR | NR | [42] |
| Placebo | 7.3 | NR | NR | NR | NR | NR | |||
| JAVELIN | 1 | Avelumab PD-L1+ | NR | NR | NR | 17.1 | NR | 14.3 | [43] |
| Avelumab PD-L1- | NR | NR | NR | 7.4 | NR | 8.0 | |||
| Ongoing trial name | Phase | Therapy | Setting | Endpoints (starting with primary) | |||||
| NIBIT-MESO-1 | 2 | Durvalumab + tremelimumab | Unresectable malignant mesothelioma | ORR, DCR, PFS, OS (by PD-L1%), and safety. | [44] | ||||